drug
melphalan
Marketedupdated 5mo agoby Zhaoke Ophthalmology Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying melphalan
- phase2A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- phase22015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- phase3Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
- phase2Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
- phase2Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
- phase2Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- phase2Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
- phase1Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 13, 2029
~2.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Jan 30, 2034formulationUS 10040872
- Feb 27, 2033formulationUS 9493582
- Jun 14, 2030formulationUS 109401283.7y
- May 28, 2030formulationUS 108641833.6y
- May 28, 2030formulationUS 110203633.6y
- Mar 13, 2029formulationUS 84100772.4y
- Mar 13, 2029formulationUS 92000882.4y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that